An Operational Guide for GLP-1 Prescribing Under the 2026 Medicare Bridge Program

Editor's Note: The Medicare GLP-1 Bridge is an evolving federal demonstration, currently authorized through December 31, 2027. The Part D portion of the successor BALANCE Model has been delayed and no replacement has been finalized. This information is subject to change based on upcoming CMS guidance and federal rulemaking.

Key Takeaways:

• The Medicare Bridge Program formally treats obesity as a chronic disease rather than a "lifestyle" condition in the Medicare population.
• Eligibility runs on three tiers — BMI 35 and above alone, BMI 30 and above with a specified cardiometabolic condition, or BMI 27 and above with pre-diabetes or established cardiovascular disease — assessed as of therapy initiation.
• The demonstration is authorized through December 31, 2027. The Part D portion of the successor BALANCE Model has been delayed and no replacement has been finalized.

As of 2026, the obesity management landscape has undergone a seismic shift with the launch of the Medicare GLP-1 Bridge Program. For years, clinicians have navigated the "weight loss exclusion" of the Social Security Act, often leaving older patients with obesity without affordable access to life-changing incretin therapies.^1,2

The Bridge Program runs from July 1, 2026 through December 31, 2027. It is a Section 402 demonstration operating outside the Part D benefit rather than an expansion of it — plan sponsors carry no risk and do not opt in, and a single central processor handles prior authorization, claims adjudication, and pharmacy payment.^1,2

Patient eligibility and clinical criteria

The Bridge Program does not grant universal coverage for all patients with an elevated BMI. To qualify, clinicians must attest that the patient meets specific thresholds during the Prior Authorization (PA) process.^1-3

Primary eligibility categories

A patient qualifies if, at the time GLP-1 therapy was initiated, they met one of the following, and the drug is prescribed to reduce excess body weight and maintain weight reduction alongside ongoing lifestyle modification including structured nutrition and physical activity:^1-3

• BMI ≥ 35 – no additional condition required
• BMI ≥ 30 plus heart failure with preserved ejection fraction, uncontrolled hypertension (systolic above 140 mm Hg or diastolic above 90 mm Hg despite two antihypertensive medications), or chronic kidney disease stage 3a or above
• BMI ≥ 27 plus pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease

Three diagnoses disqualify a patient because they are already Part D–covered indications: type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction–associated steatohepatitis. Those patients obtain therapy through their Part D plan instead.^1-3

The prescribing workflow: Centralized processing

The most significant operational change in 2026 is that Bridge Program prescriptions do not go through the patient’s Part D plan. Instead, CMS has established a central processor to manage claims and PAs.^1-3

Operational steps for the clinic:^1-3

• Submission – Send the prescription to the pharmacy first. The pharmacy transmits the claim, determines that authorization is required, and sends the request to the prescriber electronically or by fax, typically within 24 to 72 hours. Submitting a prior authorization before a pharmacy claim exists returns a patient-not-found error.
• If no request arrives – After roughly 72 hours, the prescriber can download and submit the fax form directly.
• Denials – There is no appeals process under the demonstration. A prescriber who submitted incorrect or incomplete information resubmits the form.
• Cost to patient – A $50 copay per 30-day supply. The Part D deductible does not apply, no part of the copay accrues toward true out-of-pocket costs, and there is no low-income subsidy. For a dual-eligible patient accustomed to a $2 to $3 copay, the Bridge is more expensive at the counter, not less.

Coding and documentation essentials

While the medication is processed centrally, your clinical encounter must still be coded accurately for reimbursement and to support the medical necessity of the GLP-1 therapy.^1,4

ICD-10-CM coding

Specificity is paramount for Bridge Program audits. Always include:⁴

• E66.01 – Morbid (severe) obesity due to excess calories
• E66.3 – Overweight (for those in the BMI 27 to 29.9 range)
• Z68.XX – BMI status codes (e.g., Z68.35 for BMI 35.0 to 35.9).

CPT and HCPCS coding

For the clinical visit and ongoing obesity counseling, utilize:⁴

• G0447 – Face-to-face behavioral counseling for obesity, 15 minutes. Medicare covers this for patients with a BMI ≥ 30.
• 99213–99215 – Established patient E/M visits. Ensure documentation reflects the complexity of managing multi-system metabolic health and potential GLP-1 side effects.

Medication selection in 2026

Under the Bridge Program, coverage is limited to specific FDA-approved formulations for weight loss. As of April 2026, the following are included:^1-3

• Foundayo® (orforglipron) – Oral tablet formulation
• Wegovy® (semaglutide) – Both injectable and the newly released tablet formulations
• Zepbound® (tirzepatide) – Specifically, the KwikPen® formulation

Clinical management in older patients

Prescribing for the 65+ demographic requires a "start low, go slow" approach. Clinical data suggest that while GLP-1s are highly effective, older adults are at a higher risk for sarcopenia.⁵

When prescribing GLP-1s to older patients, clinicians should emphasize a protein-forward diet and resistance training to preserve lean body mass. Regular monitoring of renal function is also advised, especially in patients with pre-existing chronic kidney disease.⁵

Promise in treating seniors with obesity

The 2026 Medicare GLP-1 Bridge gives clinicians a defined pathway to treat obesity in the Medicare population, and mastering the prior authorization sequence, the eligibility tiers, and the specific coding is what makes it usable. It is also finite. The demonstration ends December 31, 2027, the successor model's Part D portion has been delayed, and no replacement has been finalized — so patients starting therapy now should be counseled about a coverage window rather than a transition.^1-3